Autologous haematopoietic stem cell ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Auteur(s) :
Guillaume-Jugnot, Perrine [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Badoglio, Manuela [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Labopin, Myriam [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Terriou, Louis [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Martin, Thierry [Auteur]
Lioure, Bruno [Auteur]
Marjanovic, Zora [Auteur]
Blaise, Didier [Auteur]
Nguyen, Stephanie [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Pugnet, Gregory [Auteur]
Huynh, Anne [Auteur]
Deligny, Christophe [Auteur]
Seinturier, Christophe [Auteur]
Garban, Frederic [Auteur]
Swiader, Laure [Auteur]
Bay, Jacques-Olivier [Auteur]
Braun, Thorsten [Auteur]
Peffault De Latour, Regis [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Rubio, Marie-Therese [Auteur]
Université de Lorraine [UL]
Farge, Dominique [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Badoglio, Manuela [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Labopin, Myriam [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Terriou, Louis [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Martin, Thierry [Auteur]
Lioure, Bruno [Auteur]
Marjanovic, Zora [Auteur]
Blaise, Didier [Auteur]
Nguyen, Stephanie [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Pugnet, Gregory [Auteur]
Huynh, Anne [Auteur]
Deligny, Christophe [Auteur]
Seinturier, Christophe [Auteur]
Garban, Frederic [Auteur]
Swiader, Laure [Auteur]
Bay, Jacques-Olivier [Auteur]
Braun, Thorsten [Auteur]
Peffault De Latour, Regis [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Rubio, Marie-Therese [Auteur]
Université de Lorraine [UL]
Farge, Dominique [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Titre de la revue :
Clinical Rheumatology
Nom court de la revue :
Clin. Rheumatol.
Numéro :
38
Pagination :
1501–1511
Date de publication :
2019-05-01
ISSN :
1434-9949
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: The use of autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease (AD) patients has increased progressively worldwide. We retrospectively analysed the long-term outcome of AHSCT for ...
Lire la suite >BACKGROUND: The use of autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease (AD) patients has increased progressively worldwide. We retrospectively analysed the long-term outcome of AHSCT for AD reported to the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). METHODS: All French AD patients (≥ 18 years at transplant) with a first AHSCT between 1997 and 2013 were included. Primary data were derived from the European Society for Blood and Marrow Transplantation (EBMT) registry, and additional data were obtained through a specific questionnaire designed for the study. Primary end-point was overall survival (OS). Secondary end points were progression-free survival (PFS) and non-relapse mortality (NRM). RESULTS: Ninety-four AD patients were included, of whom 71% suffered from rheumatologic diseases (n = 67, including 56 systemic sclerosis (SSc)), 16% from neurological disease (n = 15, including 14 multiple sclerosis (MS)) and 13% from various other AD (n = 12). After a median (interquartile range, IQR) follow-up of 83 months (38-130), OS at 5 and 10 years were 77% (95% CI 68.5-86.2) and 64% (95% CI 51.7-76.3), and for PFS 51% (95% CI 40.4-61.6) and 44% (95% CI 32.8-55.3), respectively. Overall, NRM was 8.7% (95% CI 4.0-15.5) at day 100, 9.8% (95% CI 4.8-16.9) at 5 years and 13.6% (95% CI 6.9-22.5) at 10 years. CONCLUSIONS: This first SFGM-TC retrospective report shows long-term benefit of AHSCT in AD patients with acceptable toxicity.Lire moins >
Lire la suite >BACKGROUND: The use of autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease (AD) patients has increased progressively worldwide. We retrospectively analysed the long-term outcome of AHSCT for AD reported to the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). METHODS: All French AD patients (≥ 18 years at transplant) with a first AHSCT between 1997 and 2013 were included. Primary data were derived from the European Society for Blood and Marrow Transplantation (EBMT) registry, and additional data were obtained through a specific questionnaire designed for the study. Primary end-point was overall survival (OS). Secondary end points were progression-free survival (PFS) and non-relapse mortality (NRM). RESULTS: Ninety-four AD patients were included, of whom 71% suffered from rheumatologic diseases (n = 67, including 56 systemic sclerosis (SSc)), 16% from neurological disease (n = 15, including 14 multiple sclerosis (MS)) and 13% from various other AD (n = 12). After a median (interquartile range, IQR) follow-up of 83 months (38-130), OS at 5 and 10 years were 77% (95% CI 68.5-86.2) and 64% (95% CI 51.7-76.3), and for PFS 51% (95% CI 40.4-61.6) and 44% (95% CI 32.8-55.3), respectively. Overall, NRM was 8.7% (95% CI 4.0-15.5) at day 100, 9.8% (95% CI 4.8-16.9) at 5 years and 13.6% (95% CI 6.9-22.5) at 10 years. CONCLUSIONS: This first SFGM-TC retrospective report shows long-term benefit of AHSCT in AD patients with acceptable toxicity.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2019-10-22T08:09:12Z
2023-12-21T10:30:11Z
2023-12-21T10:30:11Z